Through the acquisition of MMFrance and Laurypath, the company aims to expand the business of its precision cancer diagnostics company Epredia into Europe
Japanese healthcare company PHC Holdings announced that its US subsidiary Epredia has acquired anatomical pathology suppliers Microm Microtech France (MMFrance) and Laurypath, for an undisclosed sum.
The acquisition is part of the company’s strategy to expand the business of its precision cancer diagnostics company Epredia into Europe.
Established in 1987, MMFrance and Laurypath are based in Lyon, France. They are dedicated to manufacturing and supply of anatomical pathology products.
The two companies offer technical support for laboratories across the country, and locally supply reagents and other consumables used in cancer diagnostics.
Epredia president John Sweeney said: “We are pleased to bring MMFrance and Laurypath into PHC Group to contribute to the growth of Epredia’s global business.
“Our customers in anatomical pathology laboratories need a consistent supply of high-quality diagnostics products, and we are excited to be able to provide a locally manufactured option that eliminates some of the logistical challenges our industry continues to face globally.”
With the acquisition, MMFrance and Laurypath will now operate as fully owned subsidiaries of PHC Group.
Epredia will obtain Laurypath’s Europe-based tissue processing reagents and fixatives manufacturing unit, which supports both clinical and research needs.
The demand for reagents and fixatives increased due to the rise in complex oncology testing and their use in every anatomical pathology laboratory, said the company.
Epredia said that the local production and supply of anatomical pathology products will reduce the environmental footprint of its European customers.
Furthermore, PHC aims to collaborate with European university hospitals working on cancer treatment and rare disease research, which require laboratory consumables.
MMFrance founder Daniel Pierron said: “With Epredia’s global coverage of the cancer diagnostics market, it was a natural fit for our company to become part of PHC Group.
“Epredia products are used in cancer diagnostics 44 times every second, and we are proud to join one of the global leaders in anatomical pathology.”
Epredia was established in 2019 after PHC Holdings acquired Thermo Fisher Scientific’s anatomical pathology business.
It offers a portfolio of portfolio microscope slides, instruments and consumables in the US, the UK, Germany, Switzerland and China with a total of around 1,200 employees.